Literature DB >> 23891804

FMRP and myelin protein expression in oligodendrocytes.

Anthony Giampetruzzi1, John H Carson, Elisa Barbarese.   

Abstract

Fragile X syndrome (FXS) is caused by lack of expression of fragile X mental retardation protein (FMRP), the product of the Fmr1 gene. In many cases FXS is associated with abnormalities in CNS myelination. Although FMRP is expressed in oligodendrocyte progenitor cells and immature oligodendrocytes (OLGs) previous studies have not detected it in mature, myelin-producing OLGs. FMRP represses translation of myelin basic protein (MBP) RNA in vitro and is believed to prevent premature MBP expression in immature OLGs. Lack of FMRP in FXS could lead to premature myelination and/or myelin abnormalities. Here we show that FMRP is expressed in mature, MBP-positive OLGs of rodents and in MBP-positive human OLGs. We confirm that FMRP is a translational repressor of MBP mRNA in vitro, but at concentrations likely too high to be physiologically relevant in vivo. We find MBP expression in cultured Fmr1 KO OLGs to be similar to wild type, and expression of MBP and other myelin proteins in brain homogenates of the Fmr1 KO mouse to be similar to wild type before, during, and after the period of active myelination. These results suggest that while FMRP is expressed in mature OLGs, myelin abnormalities caused by lack of FMRP expression in FXS are not recapitulated in rodents.
© 2013.

Entities:  

Keywords:  Fragile X mental retardation protein; Fragile X syndrome; Myelin; Oligodendrocyte; Translation

Mesh:

Substances:

Year:  2013        PMID: 23891804      PMCID: PMC3804070          DOI: 10.1016/j.mcn.2013.07.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  34 in total

Review 1.  Higher-throughput, label-free, real-time molecular interaction analysis.

Authors:  Rebecca L Rich; David G Myszka
Journal:  Anal Biochem       Date:  2006-11-13       Impact factor: 3.365

Review 2.  Myelin basic protein: a multifunctional protein.

Authors:  J M Boggs
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

3.  Evidence that fragile X mental retardation protein is a negative regulator of translation.

Authors:  B Laggerbauer; D Ostareck; E M Keidel; A Ostareck-Lederer; U Fischer
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

4.  Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome.

Authors:  Fumiko Hoeft; John C Carter; Amy A Lightbody; Heather Cody Hazlett; Joseph Piven; Allan L Reiss
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

5.  Myelin deficiencies visualized in vivo: visually evoked potentials and T2-weighted magnetic resonance images of shiverer mutant and wild-type mice.

Authors:  Melanie Martin; Timothy D Hiltner; John C Wood; Scott E Fraser; Russell E Jacobs; Carol Readhead
Journal:  J Neurosci Res       Date:  2006-12       Impact factor: 4.164

6.  The fragile X mental retardation protein inhibits translation via interacting with mRNA.

Authors:  Z Li; Y Zhang; L Ku; K D Wilkinson; S T Warren; Y Feng
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

7.  Anatomical phenotyping in a mouse model of fragile X syndrome with magnetic resonance imaging.

Authors:  Jacob Ellegood; Laura K Pacey; David R Hampson; Jason P Lerch; R Mark Henkelman
Journal:  Neuroimage       Date:  2010-03-19       Impact factor: 6.556

8.  Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome.

Authors:  Laura K K Pacey; Laurie C Doering
Journal:  Glia       Date:  2007-11-15       Impact factor: 7.452

9.  FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A.

Authors:  Usha Narayanan; Vijayalaxmi Nalavadi; Mika Nakamoto; David C Pallas; Stephanie Ceman; Gary J Bassell; Stephen T Warren
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

10.  Early white-matter abnormalities of the ventral frontostriatal pathway in fragile X syndrome.

Authors:  Brian W Haas; Naama Barnea-Goraly; Amy A Lightbody; Swetapadma S Patnaik; Fumiko Hoeft; Heather Hazlett; Joseph Piven; Allan L Reiss
Journal:  Dev Med Child Neurol       Date:  2009-03-24       Impact factor: 5.449

View more
  13 in total

1.  Conditional knockout of TOG results in CNS hypomyelination.

Authors:  Michael J Maggipinto; Joshay Ford; Kristine H Le; Jessica W Tutolo; Miki Furusho; John W Wizeman; Rashmi Bansal; Elisa Barbarese
Journal:  Glia       Date:  2017-01-07       Impact factor: 7.452

Review 2.  Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development.

Authors:  Richa Hanamsagar; Staci D Bilbo
Journal:  J Steroid Biochem Mol Biol       Date:  2015-10-23       Impact factor: 4.292

3.  Missing in Action: Dysfunctional RNA Metabolism in Oligodendroglial Cells as a Contributor to Neurodegenerative Diseases?

Authors:  Peter Hoch-Kraft; Jacqueline Trotter; Constantin Gonsior
Journal:  Neurochem Res       Date:  2019-03-06       Impact factor: 3.996

4.  PARP1-mediated PARylation activity is essential for oligodendroglial differentiation and CNS myelination.

Authors:  Yan Wang; Yanhong Zhang; Sheng Zhang; Bokyung Kim; Vanessa L Hull; Jie Xu; Preeti Prabhu; Maria Gregory; Veronica Martinez-Cerdeno; Xinhua Zhan; Wenbin Deng; Fuzheng Guo
Journal:  Cell Rep       Date:  2021-10-05       Impact factor: 9.995

5.  The RNA binding protein fragile X mental retardation protein promotes myelin sheath growth.

Authors:  Caleb A Doll; Katie M Yergert; Bruce H Appel
Journal:  Glia       Date:  2019-10-18       Impact factor: 7.452

6.  Quantitative profiling of brain lipid raft proteome in a mouse model of fragile X syndrome.

Authors:  Magdalena Kalinowska; Catherine Castillo; Anna Francesconi
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

7.  Persistent astrocyte activation in the fragile X mouse cerebellum.

Authors:  Laura K K Pacey; Sihui Guan; Sujeenthar Tharmalingam; Christian Thomsen; David R Hampson
Journal:  Brain Behav       Date:  2015-09-25       Impact factor: 2.708

Review 8.  Altered Translational Control of Fragile X Mental Retardation Protein on Myelin Proteins in Neuropsychiatric Disorders.

Authors:  Se Jin Jeon; Jong Hoon Ryu; Geon Ho Bahn
Journal:  Biomol Ther (Seoul)       Date:  2017-05-01       Impact factor: 4.634

Review 9.  Developmental studies in fragile X syndrome.

Authors:  Khaleel A Razak; Kelli C Dominick; Craig A Erickson
Journal:  J Neurodev Disord       Date:  2020-05-02       Impact factor: 4.025

10.  Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.

Authors:  Shimriet Zeidler; Helen de Boer; Renate K Hukema; Rob Willemsen
Journal:  Front Mol Neurosci       Date:  2017-11-07       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.